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Case report
　Azacitidine has been recently recommended as a 
frontline therapy for intermediate-2 and high-risk 
myelodysplastic syndrome (MDS)1), 2). Generaly, most 
hematologists consider that azacitidine is used safely 
and easily as compared with other anticancer 
drugs1), 2). However, potentialy serious complications 
have been reported recently3). Here, we report a case 
of high-risk MDS that developed fatal bone marrow 
necrosis after granulocyte colony-stimulating factor 
(G-CSF) and azacitidine combination therapy.
　A 78-year-old woman developed pancytopenia 
during treatment for nontuberculous mycobacteria. 
Laboratory findings on the first visit showed platelets 
of 5.7 × 109/L, white blood cels of 1,700 × 109/L 
(blasts: 0%), and hemoglobin of 6.8 g/dL. Bone 
marrow aspiration (BMA) showed trilineage dysplasia 
and 13% blasts. There was no evidence of bone 
marrow necrosis at this time. The patient was 
diagnosed as refractory anemia with excess blasts-2 
and high risk according to IPSS. Azacitidine was 
administered for 7 days via intravenous injection 
folowing the manufacturer’s usage instructions after 
administration of G-CSF 75 μg/day for 4 days. Two 
days after the third course, she had a high fever (40
℃) and intolerable generalized bone pain. Laboratory 
findings showed platelets of 9 × 109/L, white blood 
cels of 2.17 × 109/L (blasts: 2.5%), hemoglobin of 6.6 
g/dL, lactate dehydrogenase (LDH) of 2,391 U/L, and 
alkaline phosphatase of 1,280 U/L (Table 1). Her bone 
marrow demonstrated difuse necrosis with sheets of 
ghost cels; these cultures were negative. She died 13 
days after the third course.
　In postmortem examination, her bone marrow 
demonstrated widespread necrosis in the lumbar 
vertebrae and sternum. Wel-preserved areas of bone 
marrow alternated with patchy foci containing 
eosinophilic ghost cels (Figure 1). No granulomas or 
thrombi were distinguishable in her bone marrow. 
These findings were consistent with a diagnosis 
of bone marrow necrosis (BMN) by leukemic 
transformation. 
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　Azacitidine, which has the capacity to induce DNA hypomethylation in vitro, is currently available for 
treatment of myelodysplastic syndrome (MDS). As a result of some trials, azacitidine has been recently 
recommended as a frontline therapy for elderly patients with high-risk and very high-risk MDS1), 2). The 
commonly encountered side efects of azacitidine are manageable1), 2). However, potentialy serious 
complications have been recently reported3). We now describe fatal bone marrow necrosis folowing 
azacitidine and granulocyte colony-stimulating factor administration in a patient with high-risk MDS.
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Discussion
　BMN is reportedly associated with anticancer drugs 
and some cytokines (e.g., high-dose G-CSF) as a 
background to disease progression4)－9). In our patient, 
G-CSF, with a dosage lower for her than in cases 
reported thus far, and azacitidine combination 
therapies were performed safely until the second 
course. However, leukemic cels increased silently and 
suddenly in her bone marrow, even though we 
carefuly administered azacitidine according to the 
manufacturer’s usage instructions. BMN does not 
develop in al high-risk MDS patients. In ours, the 
rapid leukemia cel growth may reflect a synergistic 
efect of G-CSF and azacitidine because both agents 
have the efect of inducing cel diferentiation. In 
addition, it has the efect of up-regulating the 
expression of the c-abl gene and IL-6 to bone marrow 
stromal  cels  directly;  azacitidine　 might  have 
an adverse efect on the bone marrow microen-
vironment10).
　Azacitidine, with the potential to cause serious side 
efects, may be used in combination with other drugs, 
as there is an unknown part of the mechanism of 
action of this agent. We think BMA is the only way 
to confirm the transformation to leukemia with 
azacitidine. To perform azacitidine therapy safely, we 
suggest performing BMA during each course of 
azacitidine, with or without change of state.
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The clinical course of the patient. A high fever, bone pain, LDH and 
high ALP appeared after the start of the third course of azacitidine.
Figure 1.
Bone marrow examination 11 days 
after the third course of azacitidine 
therapy showing necrotic and eosino-
philic cel ghosts at antemortem (May-
Giemsa stain x 200).
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